Clinical trial
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
NCT00839332 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- December 31, 2013
- Enrollment
- 157 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.